Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cumulative risk of developing a new symptom in patients with primary biliary cholangitis and its impact on prognosis.
Kimura N, Setsu T, Arao Y, Sakai N, Watanabe Y, Abe H, Kamimura H, Sakamaki A, Yokoo T, Kamimura K, Tsuchiya A, Osaki A, Igarashi K, Waguri N, Yanagi M, Takahashi T, Sugitani S, Kobayashi Y, Takamura M, Yoshikawa A, Ishikawa T, Yoshida T, Watanabe T, Bannai H, Kubota T, Funakoshi K, Wakabayashi H, Kurita S, Ogata N, Watanabe M, Mita Y, Mori S, Sugiyama M, Miyajima T, Takahashi S, Sato S, Ishizuka K, Ohta H, Aoyagi Y, Terai S. Kimura N, et al. Among authors: mori s. JGH Open. 2022 Jul 15;6(8):577-586. doi: 10.1002/jgh3.12789. eCollection 2022 Aug. JGH Open. 2022. PMID: 35928695 Free PMC article.
Changes in disease characteristics of primary biliary cholangitis: An observational retrospective study from 1982 to 2016.
Takamura M, Matsuda Y, Kimura N, Takatsuna M, Setsu T, Tsuchiya A, Osaki A, Waguri N, Yanagi M, Takahashi T, Sugitani S, Kobayashi Y, Yoshikawa A, Ishikawa T, Yoshida T, Watanabe T, Bannai H, Kubota T, Funakoshi K, Wakabayashi H, Kurita S, Ogata N, Watanabe M, Mita Y, Mori S, Sugiyama M, Miyajima T, Takahashi S, Sato S, Ishizuka K, Ohta H, Aoyagi Y, Terai S; Niigata PBC Study Group. Takamura M, et al. Among authors: mori s. Hepatol Res. 2021 Feb;51(2):166-175. doi: 10.1111/hepr.13586. Epub 2020 Nov 28. Hepatol Res. 2021. PMID: 33126288
[Gemcitabine treatment in patients with stage IV pancreatic cancer and prognostic factors for survival of patients with stage IVb(a retrospective survey at 15 hospitals in Niigata Prefecture)].
Ohta H, Shioji K, Maruyama Y, Watanabe K, Aiba T, Baba Y, Seki K, Yanagi M, Iiri T, Ishizuka K, Isokawa O, Nakamura A, Natsui M, Furukawa K, Suzuki Y, Ban-Nai H, Motoyama N, Mori S, Aoyagi Y. Ohta H, et al. Among authors: mori s. Gan To Kagaku Ryoho. 2008 Dec;35(13):2357-61. Gan To Kagaku Ryoho. 2008. PMID: 19098402 Japanese.
Malignant potential of hepatic angiomyolipoma: case report and literature review.
Kamimura K, Oosaki A, Sugahara S, Mori S, Moroda T, Satoh O, Morita T, Kimura K, Kamura T, Nomoto M, Aoyagi Y. Kamimura K, et al. Among authors: mori s. Clin J Gastroenterol. 2010 Apr;3(2):104-10. doi: 10.1007/s12328-010-0136-2. Epub 2010 Feb 10. Clin J Gastroenterol. 2010. PMID: 26190004
Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients.
Takimoto M, Ohkoshi S, Ichida T, Takeda Y, Nomoto M, Asakura H, Naito A, Mori S, Hata K, Igarashi K, Hara H, Ohta H, Soga K, Watanabe T, Kamimura T. Takimoto M, et al. Among authors: mori s. Dig Dis Sci. 2002 Jan;47(1):170-6. doi: 10.1023/a:1013244326874. Dig Dis Sci. 2002. PMID: 11837720
Sustained biochemical remission after interferon treatment may closely be related to the end of treatment biochemical response and associated with a lower incidence of hepatocarcinogenesis.
Suzuki K, Ohkoshi S, Yano M, Ichida T, Takimoto M, Naitoh A, Mori S, Hata K, Igarashi K, Hara H, Ohta H, Soga K, Watanabe T, Kamimura T, Aoyagi Y. Suzuki K, et al. Among authors: mori s. Liver Int. 2003 Jun;23(3):143-7. doi: 10.1034/j.1600-0676.2003.00822.x. Liver Int. 2003. PMID: 12955876
5,245 results